Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Johnson WT, Ganesan N, Epstein-Peterson ZD, Moskowitz AJ, Stuver RN, Maccaro CR, Galasso N, Chang T, Khan N, Aypar U, Lewis NE, Zelenetz AD, Palomba ML, Matasar MJ, Noy A, Hamilton AM, Hamlin P, Caron PC, Straus DJ, Intlekofer AM, Lee Batlevi C, Kumar A, Owens CN, Sauter CS, Falchi L, Lue JK, Vardhana SA, Salles G, Dogan A, Schultz ND, Arcila ME, Horwitz SM. Johnson WT, et al. Blood Adv. 2023 Sep 12;7(17):5172-5186. doi: 10.1182/bloodadvances.2023009953. Blood Adv. 2023. PMID: 37078708 Free PMC article.
Retrospective characterization of nodal marginal zone lymphoma.
Stuver R, Drill E, Qualls D, Okwali M, Lee Batlevi C, Caron PC, Dogan A, Epstein-Peterson ZD, Falchi L, Hamlin PA, Horwitz SM, Imber BS, Intlekofer AM, Johnson WT, Khan N, Kumar A, Lahoud OB, Lue JK, Matasar MJ, Moskowitz AJ, Noy A, Owens CN, Palomba ML, Schöder H, Vardhana SA, Yahalom J, Zelenetz AD, Salles G, Straus DJ. Stuver R, et al. Blood Adv. 2023 Sep 12;7(17):4838-4847. doi: 10.1182/bloodadvances.2022009587. Blood Adv. 2023. PMID: 37307213 Free PMC article. Review.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Epstein-Peterson ZD, Drill E, Aypar U, Batlevi CL, Caron P, Dogan A, Drullinsky P, Gerecitano J, Hamlin PA, Ho C, Jacob A, Joseph A, Laraque L, Matasar MJ, Moskowitz AJ, Moskowitz CH, Mullins C, Owens C, Salles G, Schöder H, Straus DJ, Younes A, Zelenetz AD, Kumar A. Epstein-Peterson ZD, et al. Haematologica. 2024 Apr 1;109(4):1149-1162. doi: 10.3324/haematol.2023.282898. Haematologica. 2024. PMID: 37646671 Free PMC article. Clinical Trial.
Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Epstein-Peterson ZD, Drill E, Aypar U, Batlevi CL, Caron P, Dogan A, Drullinsky P, Gerecitano J, Hamlin PA, Ho C, Jacob A, Joseph A, Laraque L, Matasar MJ, Moskowitz AJ, Moskowitz CH, Mullins C, Owens C, Salles G, Schöder H, Straus DJ, Younes A, Zelenetz AD, Kumar A. Epstein-Peterson ZD, et al. Haematologica. 2024 Aug 1;109(8):2749-2752. doi: 10.3324/haematol.2024.285845. Haematologica. 2024. PMID: 39087412 Free PMC article. No abstract available.
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.
Cassanello G, Drill E, Rivas-Delgado A, Okwali M, Isgor I, Caron PC, Epstein-Peterson Z, Ghione P, Hamlin P, Lue J, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Moskowitz A, Noy A, Owens C, Palomba LM, Torka P, Galera P, Zelenetz AD, Salles G, Falchi L. Cassanello G, et al. Haematologica. 2025 Feb 1;110(2):439-447. doi: 10.3324/haematol.2024.285600. Haematologica. 2025. PMID: 39234863 Free PMC article.
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes.
Lue JK, Luttwak E, Rivas-Delgado A, Irawan H, Boardman A, Caron PC, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Moskowitz A, Noy A, Palomba ML, Steiner R, Stuver R, Torka P, Vardhana S, Zelenetz AD, Schoder H, Imber B, Yahalom J, Zhang Y, Galera P, Dogan A, Aypar U, Salles G. Lue JK, et al. Blood Cancer J. 2024 Oct 14;14(1):178. doi: 10.1038/s41408-024-01148-x. Blood Cancer J. 2024. PMID: 39402034 Free PMC article. No abstract available.
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
Ryan CE, Zon RL, Redd R, Fisher DC, Shouval R, Kumar A, Crombie JL, Sadrzadeh H, Kim AI, Nayak L, Chukwueke UN, Jacobson CA, Frigault MJ, Palomba ML, Armand P, Epstein-Peterson Z, Merryman RW. Ryan CE, et al. Br J Haematol. 2023 Dec;203(5):774-780. doi: 10.1111/bjh.19037. Epub 2023 Aug 16. Br J Haematol. 2023. PMID: 37584155 Free PMC article.
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Torka P, Feldman T, Savage KJ, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Capadona C, Subzwari S, Galasso N, Yang J, Post M, Boardman A, Caron P, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Lue J, Noy A, Owens C, Palomba ML, Salles GA, Steiner R, Stuver R, Vardhana S, Yahalom J, Dogan A, Zelenetz AD, Schöder H, Moskowitz AJ. Torka P, et al. J Clin Oncol. 2025 Mar 10;43(8):985-993. doi: 10.1200/JCO-24-01278. Epub 2024 Dec 11. J Clin Oncol. 2025. PMID: 39661923 Clinical Trial.
43 results